ReviewCurrent heart failure reports2010
Neuregulin signaling and heart failure.
Review in Current heart failure reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 30 citations in OpenAlex.
- High-intensity interval training enhanced cardioprotective effects of neuregulin-1 against doxorubicin-induced cardiotoxicity.Scientific reports · 2026Article
- Hyperoside Protects Trastuzumab-Induced Cardiotoxicity via Activating the PI3K/Akt Signaling Pathway.Cardiovascular drugs and therapy · 2025Article
- Machine Learning in Identifying Marker Genes for Congenital Heart Diseases of Different Cardiac Cell Types.Life (Basel, Switzerland) · 2024Article
- The Molecular Mechanisms of Cardiotoxicity Induced by HER2, VEGF, and Tyrosine Kinase Inhibitors: an Updated Review.Cardiovascular drugs and therapy · 2022Review
- The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer Treatment.Frontiers in cardiovascular medicine · 2021Review
- Cardiac Nonmyocyte Cell Functions and Crosstalks in Response to Cardiotoxic Drugs.Oxidative medicine and cellular longevity · 2017Review
- Implications of Autophagy and Oxidative Stress in Trastuzumab-Mediated Cardiac Toxicities.Austin pharmacology & pharmaceutics · 2017Article
- Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?Human vaccines & immunotherapeutics · 2016Article
- The Src homology and collagen A (ShcA) adaptor protein is required for the spatial organization of the costamere/Z-disk network during heart development.The Journal of biological chemistry · 2015Article
- The roles of neuregulin-1 in cardiac development, homeostasis, and disease.Biomarker insights · 2015Review
- Gene transfer of human neuregulin-1 attenuates ventricular remodeling in diabetic cardiomyopathy rats.Experimental and therapeutic medicine · 2013Article
- Novel biomarkers in chronic heart failure.Nature reviews. Cardiology · 2012Review
- The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy.Chemotherapy research and practice · 2012Article
- The ShcA phosphotyrosine docking protein uses distinct mechanisms to regulate myocyte and global heart function.Circulation research · 2011Article
- Trastuzumab-induced cardiac dysfunction: A 'dual-hit'.Experimental and clinical cardiology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuregulin-1 (NRG-1), a ligand of receptor tyrosine kinases of the ErbB family, plays a critical role in cardiovascular development and maintenance of adult heart function. Results from cellular, animal, and clinical experiments have shown NRG-1 to be a promising drug candidate for restoring cardiac function after cardiac injury. Various mechanisms have been suggested to be involved in this process, such as improving sarcomeric structure or cell-cell adhesion, promoting proliferation and survival of cardiac myocytes, balancing Ca(2+) homeostasis, modulating inotropic effects, promoting angiogenesis, and preventing atherosclerosis. However, the contribution of these effects to the restoration of cardiac function remains to be estimated, and it may depend on the specific events that led to heart failure. Meanwhile, distinct and crossed signaling pathways downstream of NRG-1 may play a role in these underlying mechanisms, resulting in a complicated network of signaling mediating the function of NRG-1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.